Kyverna Therapeutics, Inc.

US$4.88As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:KYTXHealthcare
Country USA
PE (Fwd) •••
TSR 3Y CAGR (47.16%)
Div yield —
ROE (87.24%)
Biotechnology
Beta (5Y) 2.13
PE TTM —
TSR TTM (29.99%)
Mkt cap US$301.8M
ROIC (51.09%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$5.86
20.03%
(80.03%)
Hold 1|10|7|8|5
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.10
0.10
0.11
0.11
20.98%
7.01%
22.45%
25.60%
Revenue$M
18.46
17.96
18.38
18.33
7.51%
6.14%
6.27%
4.25%
Peers (US$301.8M)
Cap (US$)
PE
301.1M
76.93x
Capital
TTM
5Y
10Y
Leveragex
0.469
(0.294)
(0.190)
EBIT/Intx
0.286
0.212
0.185
Own earn%
(13.13)
160.13
168.89
Sh yield%
45.80
46.57
44.04
Owners
Insiders/Inst%
5.95
83.10
Short interest%
1.34
SBC / revenue%
1.90
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
13
Op margin range%
8–14
$1 testx
—
Incr. ROIC%
11